Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy

Blood (2019) 134 (24): 2218–2222.

https://doi.org/10.1182/blood.2019002610

Published: 2019

Includes: Supplemental data

Journal Articles

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Blood (2018) 132 (6): 587–597.

https://doi.org/10.1182/blood-2018-03-840132

Published: 2018

Includes: Supplemental data

Journal Articles

Combined Analysis of 3,664 Patients with Multiple Myeloma (MM) from Latin America (LA) and Asia

Blood (2017) 130 (Supplement 1): 5386.

https://doi.org/10.1182/blood.V130.Suppl_1.5386.5386

Published: 2017

Journal Articles

Treatment Patterns and Associated Outcomes in Patients with Relapsed or Refractory Multiple Myeloma in the US and Non-US Countries: Findings from Preamble

Ravi Vij, MD MBBS, Clara Chen, PhD BS, MS, Sergey Popov, Brian Durie, Gordon Cook, MD PhD, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Catherine Davis, Hartmut Goldschmidt, MD

Blood (2017) 130 (Supplement 1): 3123.

https://doi.org/10.1182/blood.V130.Suppl_1.3123.3123

Published: 2017

Journal Articles

An Ongoing, Observational Cohort Study in Multiple Myeloma (PREAMBLE): Preliminary Efficacy Analyses in Patients with 1 Line of Prior Therapy

Brian Durie, MD, David J Kuter, MD DPhil, Catherine Davis, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Hartmut Goldschmidt, Ravi Vij, Sergey Popov, David Cella, PhD, Gordon Cook, MD PhD

Blood (2016) 128 (22): 2403.

https://doi.org/10.1182/blood.V128.22.2403.2403

Published: 2016

Journal Articles

Prospective Investigation of Genetic Alterations in Osteolytic Lesions Compared to Paired Random Aspirates

Sandra Sauer, MD, Jens Hillengass, MD, Barbara Wagner, Daniel Spira, MD, Marc Andre Weber, MD, Stefan Hemmer, Stefan Delorme, MD, Jennifer Mosebach, MD, Martin Freitag, MD, Antonia Strauss-Dimitrakopoulou, Hartmut Goldschmidt, MD, Mindaugas Andrulis, MD, Brian Durie, MD, Dirk Hose, MD, Anja Seckinger, MD

Blood (2016) 128 (22): 4419.

https://doi.org/10.1182/blood.V128.22.4419.4419

Published: 2016

Journal Articles

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

Brian Durie, MD, Antje Hoering, PhD, S. Vincent Rajkumar, MD, Muneer H. Abidi, MD, Joshua Epstein, DSc, Stephen P. Kahanic, MD, Mohan C. Thakuri, MD, Frederic J Reu, Christopher M. Reynolds, MD, Rachael Sexton, MS, Robert Z. Orlowski, PhD, MD, Bart Barlogie, MD PhD, Angela Dispenzieri, MD

Blood (2015) 126 (23): 25.

https://doi.org/10.1182/blood.V126.23.25.25

Published: 2015

Journal Articles

Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

Juan A Flores-Montero, MD, Bruno Paiva, PhD, Luzalba Sanoja-Flores, M.Sc., Noemi Puig, MD PhD, Omar García, PhD, Sebastian Böttcher, MD PD, José J Pérez-Morán, Maria Belen Vidriales, MD PhD, Maria-Victoria Mateos, Ramon Garcia-Sanz, MD PhD, Cristina Jimenez, BsC, Marcos González, MD PhD, Joaquin Martinez-López, MD PhD, María Consuelo Cañizo, MD PhD, Jesus San Miguel, MD PhD, Brian Durie, MD, Jacques J.M. van Dongen, Alberto Orfao, MD PhD

Blood (2015) 126 (23): 367.

https://doi.org/10.1182/blood.V126.23.367.367

Published: 2015

Journal Articles

An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival

Gordon Cook, MD PhD, David Cella, PhD, Brian Durie, MD, Hartmut Goldschmidt, MD, David Kuter, MD DPhil, Philippe Moreau, Ravi Vij, MD MBBS, Catherine Davis, Abderrahim Oukessou, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Sergey Popov, Antonio Palumbo, MD

Blood (2015) 126 (23): 2093.

https://doi.org/10.1182/blood.V126.23.2093.2093

Published: 2015

Journal Articles

A New Multinational Observational Study In Multiple Myeloma: Initial Report Of The PREAMBLE Study

Ravi Vij, MD, Mehdi M. Moezi, MD, Robin Foà, MD, Gordon Cook, MD, PhD, Antonio Palumbo, MD, Hakan Kaya, MD, Brian Durie, MD, David Cella, PhD, Lieven Annemans, PhD, Yun Su, MD, Pralay Mukhopadhyay, PhD, Trong K. Le, MPH, MS, Maria Teresa Petrucci, MD

Blood (2013) 122 (21): 1964.

https://doi.org/10.1182/blood.V122.21.1964.1964

Published: 2013

Journal Articles

Response To First-Line Treatment In Stem Cell Transplant (SCT) and Non-SCT Patients With Newly Diagnosed Multiple Myeloma Who Are Enrolled In The Connect MM Registry

Rafat Abonour, MD, Jatin J. Shah, M.D., Brian Durie, MD, Howard Terebelo, DO, Cristina J Gasparetto, MD, Jayesh Mehta, MD, Mohit Narang, MD, Sachdev P Thomas, MD, Kathleen Toomey, MD, Kristen A Sullivan, MBA, CCRA, Shankar Srinivasan, PhD, Yasir Nagarwala, MD, Robert M Rifkin, MD

Blood (2013) 122 (21): 3207.

https://doi.org/10.1182/blood.V122.21.3207.3207

Published: 2013

Journal Articles

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2

Blood (2011) 117 (18): 4696–4700.

https://doi.org/10.1182/blood-2010-10-300970

Published: 2011

Journal Articles

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

Blood (2011) 117 (18): 4691–4695.

https://doi.org/10.1182/blood-2010-10-299487

Published: 2011

Journal Articles

A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid ®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.

Sundar Jagannath, MD, Bill Bensinger, MD, Robert Vescio, MD, Elber Camacho, MD, Jeffrey Wolf, MD, David Irwin, MD, Gerardo Capo, MD, Marti McKinley, MD, David H. Vesole, MD, Amitabha Mazumder, MD, John Crowley, MD, Dixie Esseltine, MD, Brian Durie, MD

Blood (2007) 110 (11): 188.

https://doi.org/10.1182/blood.V110.11.188.188

Published: 2007

Journal Articles

The Genetic Contribution to the Aetiology of Thalidomide Associated VTE.

Gareth J. Morgan, MD, PhD, David C. Johnson, BSc, John Crowley, PhD, John Shaughnessy, Jr., PhD, Pieter Sonneveld, MD, Brian Durie, MD, Christine Ramos, PhD, Brian G. Van Ness, PhD, Bart Barlogie, MD, Antje Hoering, PhD, Jeff Haessler, PhD, Dalsu Baris, MD, PhD, Michael Katz, BS, Vincent S. Rajkumar, MD, H. Goldschmidt, MD

Blood (2006) 108 (11): 246.

https://doi.org/10.1182/blood.V108.11.246.246

Published: 2006

Journal Articles

Differential Antigenic Targets of Anti-Tumor Immune Response and Selective Immunity to Stem Cell Associated Group B SOX Proteins in Preneoplastic Versus Malignant Gammopathy.

Radek Spisek, Lyn-Chi Chen, Matthew Scanlan, Andrew Simpson, Gerd Ritter, Erik Rasmussen, Jason McCoy, Anne Murray, Joseph Krasovsky, Brian Durie, John Crowley, Amitabha Mazumder, Sundar Jagannath, Bart Barlogie, Ali Gure, Madhav Dhodapkar

Blood (2005) 106 (11): 5116.

https://doi.org/10.1182/blood.V106.11.5116.5116

Published: 2005

Journal Articles

Gene Expression Profiling of Bulk CD138+ Plasma Cells in Preneoplastic Gammopathy/Asymptomatic Myeloma Identifies Distinct Subsets of Patients.

Madhav V. Dhodapkar, Fenghuang Zhan, Erik Rasmussen, Bart Burington, Brian Durie, John Crowley, Bart Barlogie, John Shaughnessy

Blood (2005) 106 (11): 1218.

https://doi.org/10.1182/blood.V106.11.1218.1218

Published: 2005

Journal Articles

SNP Genotypes Show Association with Common Toxicities during both VAD Induction and High Dose Melphalan with Autologous Transplant Support in Intergroup Trial S9321 for Myeloma: From the Bank on a Cure.

Brian G. Van Ness, John C. Crowley, Christine Ramos, Suzanne Grindle, Erik Rasmussen, Antje Hoering, Philip Greipp, Bart Barlogie, Brian Durie

Blood (2005) 106 (11): 3488.

https://doi.org/10.1182/blood.V106.11.3488.3488

Published: 2005

Journal Articles

SNP Genotypes as Prognostic Factors Associated with Staging in Myeloma: The First Combined SNP Association Analysis of SWOG, ECOG, and MRC Clinical Trials from the Bank on a Cure.

Brian Van Ness, John Crowley, Emily Blood, Erik Rasmussen, Christine Ramos, Suzanne Grindle, Gareth Morgan, David Johnson, Antje Hoering, Philip Greipp, Bart Barlogie, Brian Durie

Blood (2005) 106 (11): 3489.

https://doi.org/10.1182/blood.V106.11.3489.3489

Published: 2005

Journal Articles

Incidence, Outcomes, and SNP Genotypes Show Different Ethnic Association in Patients with Myeloma, Assessed in SWOG and ECOG Clinical Trials S9321 and E9486: From the Bank on a Cure.

Brian Van Ness, John Crowley, Christine Ramos, Suzanne Grindle, Erik Rasmussen, Emily Blood, Antje Hoering, Bart Barlogie, Philip Greipp, Brian Durie

Blood (2005) 106 (11): 506.

https://doi.org/10.1182/blood.V106.11.506.506

Published: 2005

NARROW

Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Combined Analysis of 3,664 Patients with Multiple Myeloma (MM) from Latin America (LA) and Asia

Treatment Patterns and Associated Outcomes in Patients with Relapsed or Refractory Multiple Myeloma in the US and Non-US Countries: Findings from Preamble

An Ongoing, Observational Cohort Study in Multiple Myeloma (PREAMBLE): Preliminary Efficacy Analyses in Patients with 1 Line of Prior Therapy

Prospective Investigation of Genetic Alterations in Osteolytic Lesions Compared to Paired Random Aspirates

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival

A New Multinational Observational Study In Multiple Myeloma: Initial Report Of The PREAMBLE Study

Response To First-Line Treatment In Stem Cell Transplant (SCT) and Non-SCT Patients With Newly Diagnosed Multiple Myeloma Who Are Enrolled In The Connect MM Registry

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid ®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.

The Genetic Contribution to the Aetiology of Thalidomide Associated VTE.

Differential Antigenic Targets of Anti-Tumor Immune Response and Selective Immunity to Stem Cell Associated Group B SOX Proteins in Preneoplastic Versus Malignant Gammopathy.

Gene Expression Profiling of Bulk CD138+ Plasma Cells in Preneoplastic Gammopathy/Asymptomatic Myeloma Identifies Distinct Subsets of Patients.

SNP Genotypes Show Association with Common Toxicities during both VAD Induction and High Dose Melphalan with Autologous Transplant Support in Intergroup Trial S9321 for Myeloma: From the Bank on a Cure.

SNP Genotypes as Prognostic Factors Associated with Staging in Myeloma: The First Combined SNP Association Analysis of SWOG, ECOG, and MRC Clinical Trials from the Bank on a Cure.

Incidence, Outcomes, and SNP Genotypes Show Different Ethnic Association in Patients with Myeloma, Assessed in SWOG and ECOG Clinical Trials S9321 and E9486: From the Bank on a Cure.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only